Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 633-638 , November 2009

Trastuzumab versus lapatinib: The cardiac side of the story

  • Hamdy Azim

      Affiliations

    • Department of Clinical Oncology, Cairo University Hospital, Cairo, Egypt
    • ,
  • Hatem A. Azim Jr.

      Affiliations

    • Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    • Corresponding Author InformationCorresponding author. Tel.: +20 2 33026814; fax: +20 2 33028656.
    • ,
  • Bernard Escudier

      Affiliations

    • Department of Oncology, Institute Gustave Roussy, Villejuif, Paris, France

Received 5 April 2009 ,Revised 15 June 2009 ,Accepted 22 June 2009.

References 

  1. Negro A, Brar BK, Lee KF. Essential role of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res. 2004;59:1–12
  2. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394–398
  3. Negro A, Brar BK, Gu Y, Peterson KL, Vale W, Lee KF. ErbB2 is required for G protein-coupled receptor signaling in the heart. Proc Natl Acad Sci USA. 2006;103:158889–158893
  4. Rohrbach S, Yan X, Weinberg EO, Hasan F, Bartunek J, Marchionni MA, et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation. 1999;100:407–412
  5. Azim H, Azim HA. Targeting Her-2/neu in breast cancer: as easy as this!. Oncology. 2008;74:150–157
  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  7. Piccart-Gebhart MJ, Procter M, Leyland-Jones GoldhirschA, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  8. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Eng J Med. 2007;233:2733–2743
  9. Hershman DL, Shao T. Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park). 2009;23:227–234
  10. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26:3777–3784
  11. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105:1551–1554
  12. Chien KR. Herceptin and the heart – a molecular modifier of cardiac failure. N Engl J Med. 2006;354:789–790
  13. de Azambuja E, Bedart PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learnt so far?. Target Oncol. 2009;4:77–88
  14. Untch M, Himsl I, Kahlert S, Lueck HJ, Eidtmann H, Du Bois A, et al. Anthracycline and trastuzumab in breast cancer treatment. Oncology (Williston Park). 2004;18(Suppl. 14):59–64
  15. Ewer M, Lippman S. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900–2902
  16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  17. Spielmann M, Roché H, Humblet Y, Delozier T, Bourgeois H, Serin D, et al. 3-Year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. In: Proceedings of the San Antonio breast cancer symposium, December 13–16, 2007, San Antonio, Texas; 2007 [Abs # 72].
  18. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab(AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. In: Proceedings of the San Antonio breast cancer symposium, December 8–11, 2005, San Antonio, Texas [Abs # 1].
  19. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231–1238
  20. Ewer MS. The anthracycline–trastuzumab interaction: up-regulated binding may provide vital mechanistic insight. Eur J Cancer. 2007;43:2024–2025
  21. Gianni L, Goldhirsch A, Gelber RD, Azambuja E, Procter M, Untch M, et al. Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer. Breast. 2009;18(Suppl. 1):S25;[abstract #]
  22. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679–686
  23. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26:5544–5552
  24. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an antiangiogenic cocktail. Nature. 2002;416:279–280
  25. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10:5650–5655
  26. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459–465
  27. Valero V, Gill E, Paton V, Chang Y, Buzdar AU, Park G, et al. Normal cardiac biopsy results following co-administration of doxorubicin (A), cyclophosphamide (C) and trastuzumab (H) to women with HER2-positive metastatic breast cancer. J Clin Oncol. 2004;23:72;[abstract #]
  28. Gordon MS, Matei D, Aghajanian C, Matulonis US, Brewer M, Fleming GF, et al. Clinical activity of pertuzumab (rhMAB 2C4), a HER dimerization inhibitor, in advanced ovarian activity: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24:4324–4332
  29. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, et al. Efficacy and safety of single agent pertuzumab (rhuMAB), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007;25:675–681
  30. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007;13:6175–6181
  31. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  32. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmakinetics of trastuzumab monotherapy administrated on a 3-weekly schedule. J Clin Oncol. 2005;23:2162–2171
  33. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26:2999–3005
  34. Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens. Ann Oncol. 2009;20:1026–1031
  35. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Brit J Cancer. 2006;94:247–252
  36. Gomez HL, Chavez MA, Doval DC, Nag S, Chow LW, Chang PC, et al. Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer. Breast Cancer Res Treat. 2006;100(Suppl. 1):S68
  37. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated for of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99:628–638
  38. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004;37:449–471
  39. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat. 1999;57:237–243
  40. Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002;8:347–353
  41. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rameh M, et al. Activity of the dual kinase inhibitor lapatnib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630–1639
  42. O’Shaughnessy J, Blackwell KL, Burstein H, Storniolo G, Sledge G, Baselga J, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008;26:1015;[abstract #]
  43. Dang CT, Lin NU, Lake D, Dickler MN, Modi S, Seidman AD, et al. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). J Clin Oncol. 2008;26:518;[abstract #]
  44. Schoffstall B, Chase PB. Increased intracellular (dATP) enhances cardiac contraction in embryonic chick cardiomyocytes. J Cell Biochem. 2008;104:2217–2227
  45. Shell SA, Lyass L, Rusk PB, Pry KJ, Wappel RL, Bacus SS. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle. 2008;7:1769–1775
  46. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increased in 5′-AMP-activated protein kinase inhiition of acetyl-CoA carboxylase. J Biol Chem. 1995;270:17513–17520
  47. Kudo N, Gillespie JG, Kung L, Witters LA, Schulz R, Clanachan AS, et al. Characterization of 5′-AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta. 1996;1201:67–75
  48. Cahill CM, Tzivion G, Nusrin N, Ogg S, Dore J, Ruvkun G, et al. Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14-3-3-dependent and 14-3-3-independent pathways. J Biol Chem. 2001;276:13402–13410
  49. Ozcelik C, Erdmann B, Pitz B, Wettschureck N, Britsch S, Hubner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA. 2002;99:8880–8885
  50. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol. 2004;44:2231–2238
  51. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev. 2002;7:115–130
  52. Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA. 2007;104:10607–10612
  53. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2 overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630–1639
  54. Zhou X, Wang W, Li J. Ca2+- and protein kinase C-dependent signaling pathway for nuclear factor-kappaB activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide-stimulated rat peritoneal macrophages. J Biol Chem. 2006;281:31337–31347
  55. Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther. 2008;8:1883–1890

PII: S0305-7372(09)00094-2

doi: 10.1016/j.ctrv.2009.06.007

Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 633-638 , November 2009

Article Tools

* Image Usage & Resolution